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Abstract
Background: Defects in skin barrier function are associated with an increase risk of eczema and atopic
sensitisation. Ceramide-dominant triple lipid mixture may improve and maintain the infant skin barrier function,
and if shown to be safe and feasible, may therefore offer an effective approach to reduce the incidence of eczema
and subsequent atopic sensitisation. We sort to assess the safety and compliance with daily application of a
ceramide-dominant triple lipid formula (EpiCeram™) commencing in the neonatal period for the prevention of
eczema.
Methods: Ten infants (0-4 weeks of age) with a family history of allergic disease were recruited into an open-label,
phase one trial of daily application of EpiCeram™ for six weeks. The primary outcomes were rate of compliance
and adverse events. Data on development of eczema, and physiological properties of the skin (transepidermal
water loss, hydration, and surface pH) were also measured.
Results: Eighty percent (8/10) of mothers applied the study cream on 80% or more of days during the six week
intervention period. Though a number of adverse events unrelated to study product were reported, there were no
adverse skin reactions to the study cream.
Conclusions: These preliminary results support the safety and parental compliance with daily applications of a
ceramide-dominant formula for the prevention of eczema, providing the necessary ground work for a randomised
clinical trial to evaluate EpiCeram™ for the prevention of eczema.
Trial registration: The study was listed at the Australian/New Zealand Clinical Trial Registry (ANZCTR): reg. no.
ACTRN12609000727246.
Keywords: Eczema prevention, Eczema, Skin barrier function, Asthma, Atopy
Background
There is growing awareness of the importance of skin
barrier function in the aetiology of eczema [1]. A num-
ber of genetic variants that result in null expression of
filaggrin, are associated with impaired skin-barrier func-
tion, increased risk of eczema, and eczema further com-
plicated by asthma [2,3]. The majority of childhood
eczema commences within the first six months of life
[4], and even healthy infants display lower skin barrier
function than adults [5]. Interventions in early life that
improve skin barrier could also reduce the risk of
asthma and allergic rhinitis, by reduction in risk of sen-
sitisation across a defective skin barrier [1,6] or by redu-
cing the release of pro-inflammatory cytokines that
induce airway inflammation, such as thymic stromal
lymphopoietin, by eczematous skin [7].
Lipid mixtures that contain the major lipid components
of human skin (ceramides, cholesterol and free fatty
acids), at physiological concentrations, have been shown
to greatly accelerate the restoration of barrier function
(> 90% at four hours following application) in a murine
model [8]. One such cream, EpiCeram™, has been
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ity over a 28 day treatment period as a moderate strength
topical steroid cream (fluticasone propionate 0.05%) [9]
in children (over six months of age) with moderate to
severe eczema. Although regular ceramide-dominant
treatment of neonatal skin would appear to offer the
greatest likelihood of improving the skin barrier of
infants, the safety and efficacy of such a cream as a pre-
ventive strategy on newborns is yet to be demonstrated.
We sought to establish the compliance of parents with
daily application of EpiCeram™ to their newborn baby’s
skin, and to generate initial evidence that this interven-
tion is safe for use on newborns. This information
would help establish the feasibility of regular use of
such an emollient to prevent eczema.
Methods
Trial design
This was a non-controlled (all participants treated), open
label (parents of participants and study staff all knew the
treatment status of all children), phase 1 study. The trial
was registered with the Australian and New Zealand Clini-
cal Trials Registry (ACTRN12609000727246, 24/8/08).
Mother-baby pairs were enrolled if the parent reported
that the child had a first degree relative with a history of
eczema, asthma, allergic rhinitis, or food allergy. Infants
were excluded if they had a parent with a known hyper-
sensitivity to any of the ingredients of EpiCeram™,w e r ea
multiple birth, premature (< 36 weeks gestation) or were
admitted to a special care nursery.
Recruitment
Children were enrolled in the study from birth to four
weeks of age between March and June 2010. A range of
recruitment strategies were used: a) recruitment posters
were displayed in the antenatal clinic at The Royal
Women’s Hospital (RWH) and the Departments of Allergy
Immunology and Dermatology at the Royal Children’s
Hospital (RCH), Melbourne, Australia; b) RWH Pathology
staff handed out a screening questionnaire when expectant
mothers were attending for their routine 26 week blood
tests; c) the study coordinator (Robyn Kennedy) directly
approached mothers attending antenatal clinics and while
they were on the maternity wards. The study coordinator
assessed eligibility and enrolled participants, and all
mothers provided written consent. The study was
approved by both the RCH (project 20943) and the RWH
(09/30) Human Research Ethics Committees.
Intervention
The study intervention was application of EpiCeram™
to the full skin surface of the child once per day, exclud-
ing the hands and face (ingredient list and prescribing
information found at http://www.epiceram-us.com/
prescribing-information). EpiCeram™ contains cera-
mides, cholesterol and free fatty acids at a 3:1:1 ratio
and 2% petrolatum, and has a low pH. The ceramides
used is a pseudo (ceramide N-(2-hydroxyethyl)-2-penta-
decanolylhexadecanamide. This formulation has been
approved by the Food and Drug Administration, and
has been marketed in the United States of America
since October of 2008 as a treatment of eczema. To
date, there is no evidence of toxicity from EpiCeram™.
At the request of one of the approving ethics commit-
tees, we excluded treatment of the hands and face to
minimise accidental ingestion of the cream. At the end
of the baseline assessment, all mothers were given 9 ×
30 gram tubes (270 g total) of EpiCeram™,a n dw e r e
instructed to apply approximately 6 grams (approxi-
mately a heaped teaspoon) of EpiCeram™ per applica-
t i o n ,o n c ed a i l y ,a f t e rb a t h i n gt h ei n f a n t ,o ra tar e g u l a r
time each day.
Follow-up
Parents completed a daily diary card to document applica-
tion of the study cream, as well as to note any adverse
events (particularly skin rash, redness or any other symp-
toms) that occurred. A follow-up assessment was per-
formed at approximately six weeks (5-9 weeks) following
commencement of the study cream. During this visit, the
infant’s skin was examined for signs of eczema, and the
skin barrier function (as measured by Tewameter TM300,
Courage & Khazaka, Köln), skin pH (pH-meter pH905)
and skin hydration (Corneometer CM825) were assessed
using standardized protocols. At this visit, participants
were asked to return all tubes of study cream (including
empty tubes) and these were weighed to estimate the
quantity of cream used.
Outcomes
The primary outcome was participant compliance, and
frequency of adverse events. Secondary outcomes were
presence of eczema, assessed using the UK working party
criteria [10], parent reported doctor diagnosis of eczema,
and biophysical measures of skin barrier function
(TEWL), pH, and stratum corneum hydration.
Statistical methods
T h er a t eo fc o m p l i a n c ea n dt h en u m b e ra n dn a t u r eo f
adverse events were tabulated. No statistical comparisons
were made as there was no control group.
Results
Participant flow
A total of 339 mothers were contacted to enroll 13 chil-
dren into this study (Figure 1). Parents of three infants
withdrew consent from this study following enrolment:
the stated reason in each case was ongoing concern over
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ness by the father (n = 1) to participate. In all three cases,
consent was withdrawn within seven days of enrolment
and prior to application of the study cream. The remain-
ing 10 participants attended the six week follow-up
appointment.
Participant characteristics
Anecdotally, mothers who had experienced severe aller-
gic disease themselves, or who had an older child who
had suffered from eczema, were the most interested in
participating in this study. Nine of the 10 children first
received the study cream within the first three weeks of
life (Table 1).
Compliance
Parents of eight infants applied the study cream on 80% of
the days during the intervention period (Table 1). The
remaining two infants had the cream applied on 69% and
19% of days during the six week intervention period. The
mother of the participant with the lowest rate of applica-
tion reported that the child became distressed when
undressed. There was a wide variation in the amount of
study cream that was applied in total (34 - 277 grams -
Table 1), and the average amount of cream that was used
per application (3.6 - 7.2 grams).
Six week follow-up
Two children showed evidence of facial eczema where
the study cream was not applied. No conclusions can be
drawn from the physiological data at this time due to
the lack of a control group and the small sample size
(Table 2).
There were no cases of adverse skin reactions to the
study treatment (Table 3), although a number of the
infants had skin symptoms. These were either restricted
to the face (where the study cream was not applied),
present prior to the initial application of the cream, or
noticed first on the face, and then on the child’st r u n k .
One child developed folliculitis on his face, which is not
unusual during this period of infancy in healthy infants.
A number of adverse events occurred (Table 3), includ-
ing one child who was hospitalised for bronchiolitis. All
of these events are common conditions of infancy, and
are unlikely to be related to the study treatment.
Discussion
In this phase-1 trial, most parents applied the ceramide-
dominant triple lipid mixture to the skin of their child on
most days during the study period, and there were no
major adverse reactions attributable to the intervention.
Parents were also willing to start applying the cream
within the first 2-3 weeks of life, when the skin barrier is
most compromised even in health infants [5]. Due to the
lack of a control group, no conclusions can be made con-
cerning the effect of the intervention on skin barrier,
although the obtained TEWL values appear to be substan-
tially lower than those reported previously in this age
group (mean = 9.3 g/m
2/hr, range = 7.2-10.5 for forearm
for the current study compared with mean = 26 g/m
2/hr
for infants aged 3-6 months in a prior publication [5]).
Adverse events that occurred were common conditions in
this age group and did not appear to be related to the
study treatment.
T h e r ea r ean u m b e ro fo t h e rp h a s e1a n d2t r i a l sc u r -
rently being conducted to evaluate various topical inter-
ventions for improving the skin barrier function of infants
at increased of developing eczema. One similar study is
evaluating the effects of a standard emollients (Cetaphil,
an oil-in-water cream) [11]. We have chosen an emollient
that contains ceramides, cholesterol and free fatty acids at
a 3:1:1 ratio (which also contains 2% petrolatum) and has
been formulated to correct the underlying lipid defects in
eczematous stratum corneum [12]. There is limited data
Table 1 Characteristics of the study population, and
compliance with daily application of study cream
Male infant 6/10
Number of parents with allergic disease
1 parent 9/10
2 parents 1/10
Age in weeks at: Median (IQR)*
commencement of treatment 2.1 (1.3-2.9)
follow-up 9.5 (7.6-10.1)
Application of study cream - medians (range)
days cream applied (max = 42) 38.5 days (35-42)
proportion of eligible days applied 92% (83%-100%)
total quantity applied 158 g (150-207)
average quantity applied per day 3.8 g (3.6-4.9)
average quantity applied per day on days used 4.4 g (3.8-4.9)
*IQR interquartile range.
Table 2 Trans-epidermal water loss (TEWL), skin pH,
capacitance and sebum measured at follow up
(approximately 6 weeks)
Skin parameter Median (IQR)
TEWL (g/m
2/hr)
forearm 9.3 (7.2-10.5)
forehead 14.3 (8.1-25.4)
pH
forearm 5.1 (4.8-5.4)
forehead 4.9 (4.7-5.4)
Hydration (forearm)* 45.8 (41.3-46.5)
Sebum (forehead)* 36 (22-85)
* arbitrary units of measurement
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cheaper emollients. A recent study has found that the effi-
cacy of EpiCeram was no-greater than an over the counter
petrolatum-based moisturiser (Aquaphor) for the manage-
ment of mild-to-moderate atopic dermatitis, and that the
cost effectiveness was far greater for the over the counter
formulation [13]. It should be noted that the previous
study assessed the effects of these treatments for the man-
agement of symptoms for existing eczema, rather using it
as a preventive strategy. Secondly, the observed results
were obtained by applying the treatments three times per
day [13]. It would appear unlikely that parents would be
able, or willing, to undertake such an intensive skin care
regime for the prevention of eczema.
A potential role for EpiCeram in eczema prevention is
supported by findings that: ceramide profile correlates
with eczema [14], and applied ceramides rapidly incorpo-
rate into the nucleated layers of the epidermis [15].
Furthermore, EpiCeram is formulated at an acidic pH
(5.0), as lamellar body production and secretion of cera-
mides is impaired at the high pH of eczematous skin [16].
Also, EpiCeram contains 2% petrolatum, which provides
similar benefits of pure petrolatum, but without the greasi-
ness [15], which is an important consideration for an
eczema prevention strategy.
No adverse reactions to the study cream occurred in this
small sample of infants. Although concerns have been
raised about the toxic potential of excess ceramides, the
pseudo-ceramide used in EpiCeram™ do not share these
properties [17]. There have been no reported events of
toxicity caused by EpiCeram™ in the three years of mar-
keting this product as a treatment for eczema. One of our
institutional ethics committees questioned the application
of this intervention to the face and hands of infants, due
to the risk of ingestion of the cream. However, given that
eczema generally commences on the scalp, face and neck
[18], and that two of the infants developed symptoms of
facial eczema, it will be important to apply the cream to
the full body surface, including the face and hands, in
future studies. Although the small amount of cream that
can be ingested is unlikely to cause adverse events, given
the novelty of this intervention and the vulnerability of the
participant population, we will continue to monitor the
safety of this intervention, including systemic and gastro-
intestinal reactions.
Importantly, this study provided useful information on
recruitment strategy. Recruitment into this trial proved
surprisingly difficult, as demonstrated by the high number
of mothers approached to achieve 10 children completing
this study. We also found a reasonably high rate (3/13 par-
ents) who initially consented for their child to be enrolled
in the study, but soon after decided to withdraw from the
study, which indicates that “over recruitment” will need to
be used in similar future studies. We trailed a range of
potential recruitment strategies, finding that a post-natal
approach was most efficient, due to the higher rate of
recruitment, and minimising the delay from the expression
of interest to the initiation of treatment. Anecdotally, we
also observed that parents of children with the strongest
family history of allergic disease, particularly those who
had an older child with moderate to severe eczema, were
most interested in being involved in this type of study.
This study has two important limitations. Firstly,
although we did not observe any adverse skin effects of
the study treatment, the relatively sample size means that
we cannot exclude the possibility that this treatment may
cause rarer adverse effects. Secondly, the lack of a control
group precludes us from assessing if this treatment may
help improve skin barrier function and reduce the risk of
eczema. We are currently developing further trials to
address these limitations.
Conclusions
The use of ceramide-dominant triple-lipid formulation
on the skin of starting during the neonatal period is a
novel approach to eczema and atopic disease prevention.
The treatment used in this study, EpiCeram, has been
approved by the Food and Drug authority for the treat-
ment of eczema. This pilot study supports the safety and
parental compliance with daily applications of this
Table 3 Adverse events during treatment period
Skin Symptoms Frequency Comment
Heat rash 1
Facial eczema 2 treatment not applied to face
Folliculitis 1 started on face - non treated area - and spread to trunk
Dry skin (torso, ankles, wrists) 1 present prior to first application
Other symptoms
Bronchiolitis 1 resulted in hospitalisation
Cough/fever 1
Conjunctivitis 2
Reflux 1
Cold/flu 3
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possible eczema prevention. However, recruitment
remains problematic. We are currently initiating a phase-
2/3 trial of this intervention, and we hope that this inter-
vention will improve infant skin barrier function suffi-
ciently to reduce the incidence of eczema and atopic
disease. Future studies will need to also assess the cost-
effectiveness of such strategies, including head-to-head
evaluations with cheaper, over-the-counter, formulations.
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